Skip to Content
You are currently on the new version of our website. Access the old version .
  • Tracked for
    Impact Factor
  • 24 days
    Submission to First Decision
  • 4 days
    Acceptance to Publication

Kinases and Phosphatases

Kinases and Phosphatases is an international, peer-reviewed, open access journal on every aspect of post-translational modifications in all biological systems, from bacteria to humans, covering a wide range of disciplines, including biochemistry, molecular biology, structural biology, cell biology, medicinal chemistry, pharmacology, cellular pathology, and clinical disciplines, and is published quarterly online by MDPI.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (100)

  • Article
  • Open Access

The mitogen-activated protein kinase (MAPK) cascade is crucial in transmitting extracellular signals to the nucleus, where transcriptional patterns are adjusted in response to changing environmental conditions. In barley, a specific cascade enzyme, MKK3, mediates the duration of dormancy and hence the subsequent germination of the grain. Higher activity of this HvMKK3 isoenzyme is associated with decreased grain dormancy, but also with increased risks of yield losses through pre-harvest sprouting of the grain. Previous work has shown how the MKK3 isoenzyme docks with and phosphorylates its downstream substrate HvMAPK. Here, we used computational, analytical and phylogenetic methods to generate a quaternary structural model of the barley MKK3 enzyme with its candidate upstream MAP3K, working as a structurally consistent complex. Although this model awaits confirmation, it provides a structural rationale for the binding and subsequent hydrolysis of ATP by MAP3K and the phosphorylation of Thr residues in the downstream MKK3’s activation loop. This MAP3K enzyme is encoded by a single highly conserved gene on chromosome 5H in 76 wild and domesticated barley species. Potential functions of conserved protein sequence motifs in intrinsically disordered regions of the enzyme are considered in relation to the activation and turnover of the enzyme.

Kinases Phosphatases

31 October 2026

Schematic outline of the mitogen-activated kinase cascade. Following the binding of extracellular mitogens to their plasma membrane-bound receptor, a cascade at each level is initiated in which a mitogen-activated kinase kinase kinase (MAP3K) phosphorylates and activates a mitogen-activated kinase kinase (MAPKK), which in turn phosphorylates and activates a mitogen-activated kinase (MAPK). The activated MAPK subsequently switches on transcription factors in the nucleus. Typically, MAPK cascade proteins contain catalytic modules, additional folded domains, and extended intrinsically disordered regions (IDRs) present in MAPK and MAP3K enzymes. IDRs contain Gly, Ala, Asp, Glu, Pro, and Ser residue-rich regions (shown as random black structureless lines). Redrawn from Wang and Gou [6] and Hrmova et al. [5].
  • Review
  • Open Access

Rewriting Phosphorylation Codes: Toward Signal-State Editing with PhosTACs

  • Dong-Ting Ke,
  • Wei-Chen Chang and
  • Po-Han Chen
  • + 1 author

Protein phosphorylation is a dynamic post-translational modification (PTM) that regulates protein function, signaling, and cellular behavior. Accumulating evidence indicates that combinations of phosphosites function as “phosphorylation codes,” encoding distinct conformational and signaling states rather than acting independently. Dysregulation of these phosphorylation codes contributes to numerous diseases. Although therapies targeting protein kinases and phosphatases have achieved substantial clinical success, their indirect modulation of substrate phosphorylation leaves room for improved selectivity, reduced off-target effects, and greater resilience to therapeutic resistance. Here, we integrate current concepts of phosphorylation codes as a unifying framework for understanding phosphorylation-dependent regulation. Using tau and EGFR as representative models of pathological and signaling-state encoding, we further compare conventional kinase and phosphatase inhibitors with emerging induced-proximity technologies, including targeted protein degradation (TPD) of phosphorylation regulators and phosphorylation-targeting chimeras (PhosTACs), which recruit engineered or endogenous phosphatases to achieve targeted protein dephosphorylation (TPDephos). Together, these molecular strategies represent a conceptual progression from enzyme-centered intervention to event-driven editing of substrate phosphorylation states.

Kinases Phosphatases

5 October 2026

Tau Phosphorylation Codes and Disease Implications. (A) This figure illustrates a linear domain schematic of 2N4R tau, with key phosphorylation sites annotated on the corresponding domains. (B) The priming phosphorylation code demonstrates how sequential phosphorylation events cooperate to regulate tau conformation and function. Phosphorylation at Ser235 by CDK5 facilitates subsequent phosphorylation at Thr231 by increasing its accessibility to GSK3β. Likewise, phosphorylation at Ser404 promotes sequential phosphorylation of neighboring residues, including Ser400 and Ser396, which are associated with abnormal tau aggregation and NFT deposition. (C) The tracking phosphorylation code reflects the accumulation of specific phosphorylation events that accompany tauopathies such as AD progression. Early phosphorylation of tau at Thr181, Thr217, and Thr231, detected in plasma, is associated with preclinical AD and amyloid-β plaque pathology, and the plasma pTau217/Aβ42 ratio has been incorporated into an FDA-cleared diagnostic test for AD. (D) The identification phosphorylation code suggests that phosphorylation at Ser202 and Thr205 (the AT8 epitope) may serve as a biomarker for detecting tauopathies, whereas distinct combinations of tau phosphorylation patterns, together with differences in tau isoform composition and fibril conformation, may distinguish individual tauopathies. Created in BioRender. Chen, P. (2026) https://BioRender.com/pg7j192.
  • Review
  • Open Access

Oleanolic acid (OA) is readily modified at C-3 and C-28, but mechanistic studies of its derivatives often rely on downstream signaling readouts. This review examines compound series in which structural changes can be compared with quantitative enzyme data, receptor-level measurements, or functional target dependence, with emphasis on cancer pharmacology. PTP1B-directed studies show that potency and discrimination from the closely related TCPTP are separable SAR properties; later glycoside series changed the PTP1B/TCPTP selectivity profile, while cellular anticancer activity varied independently. Among RTKs, matched C-28 phenylurea derivatives have quantitative VEGFR2 inhibition data, whereas K73-03 has an EGFR-dependent cellular phenotype supported by molecular modeling, receptor phosphorylation, EGFR knockdown, and xenograft experiments. OA dimers show linker- and C-3-acetylation-dependent cellular SAR, while FAK remains a docking-derived target hypothesis without direct kinase validation. AKT/mTOR, AMPK/mTOR, JAK/STAT3, NF-κB, and Nrf2 responses are treated as downstream context unless supported by upstream target evidence. The compounds discussed here remain preclinical, and further development requires matched subtype profiling, direct receptor assays, functional target-dependence experiments, and compound-specific pharmacokinetic evaluation.

Kinases Phosphatases

4 October 2026

Representative chemical structures of oleanolic acid derivatives included in the quantitative SAR and target-oriented comparisons discussed in this review. (A) PTP1B/TCPTP-directed series, including OA-Br-1 (2b) and compound 8 from Song et al. [12], the bidesmosidic glycoconjugates 1h, 1i, and 1j from Liu et al. [11], and compounds 10p, 11p, 12m, and 13 from the PTP1B-directed series of Zhang et al. [10]. (B) RTK-oriented compounds, including the VEGFR2-active phenylurea derivatives I6 and I7 from Song et al. [21], the PDGFR-oriented analogues OA-4 (I6) and OA-6 (II4) from Meng et al. [43], and K73-03 from Zhou et al. [20]. The composite designations used for the PDGFR series distinguish OA-4 (I6) from the structurally unrelated I6 of the VEGFR2 series. (C) Dimeric OA derivatives representing phenotypic SAR and a FAK-oriented hypothesis. The common C-28-linked dimer scaffold is shown with variable linker L and C-3 substituent R. Compounds 2a, 2d, 2e, and 2f illustrate linker-length and linker-geometry effects, whereas 3a represents the C-3-acetylated analogue of 2a [13,14,15]. For compounds 2a, 2d, 2e, and 2f, R = H; for 3a, R = Ac. FAK involvement in the dimeric series is based on molecular docking and should be regarded as a target hypothesis requiring biochemical validation [14].
  • Article
  • Open Access

Familial Alzheimer’s disease (FAD) is an accelerated form of dementia affecting cholinergic neurons. Despite several efforts, no single drug or treatment has demonstrated complete efficacy. Therefore, finding effective therapeutic agents is imperative. Previous studies have shown that the PSEN1 I416T variant induces FAD-like neuropathology in cholinergic-like neurons (ChLNs), characterized by the intracellular accumulation of the Aβ (iAβ) peptide, the oxidation of the stress sensor protein DJ-1, the abnormal phosphorylation of the tau protein at serine 202/threonine 205 (pS202/T205), the loss of mitochondrial membrane potential (ΔΨm), and activation of the pro-apoptotic proteins tumor protein 53 (TP53), Jun proto-oncogene, AP-1 transcription factor subunit (c-JUN), p53 upregulated modulator of apoptosis (PUMA), and cleaved caspase-3 (CC3). We report for the first time that PSEN1 I416T induces abnormal phosphorylation of Leucine-rich repeat kinase 2 (LRRK2) kinase at residue serine 935 (S935), concomitant with phosphorylated alpha-synuclein (αSYN) at residue serine 129 (S129) and abnormal accumulation of autophagosomes and atypical increase in vesicular lysosomal pH, thereby provoking a profound alteration in autophagy in ChLNs. Here, we also demonstrate for the first time that the potent LRRK2 inhibitor PF-06447475 (hereafter referred to as PF475) almost completely attenuated PSEN1 I416T-induced proteinopathy, oxidative stress (OS), and apoptosis and improve autophagy to an activity comparable to untreated wild-type (WT) ChLNs. Overall, PF475 restored the survival of mutant ChLNs. Taken together, these findings suggest that PF475 is an excellent pharmacological tool with which to investigate the regulation of LRRK2-associated pathological signaling in the PSEN1 I416T familial Alzheimer’s disease (FAD) model.

Kinases Phosphatases

18 September 2026

PF475 inhibits pS935-LRRK2 in wild-type (WT) and PSEN1 I416T cholinergic-like neurons (ChLNs) reducing LRRK2 phosphorylation to basal levels. WT and PSEN1 I416T MenSCs were cultured in a cholinergic differentiation medium, as described in the Section 4, in the absence or presence of PF475 (1 μM). (A–D) Representative flow cytometry density plot with density contour analysis showing phosphorylated LRRK2-positive cells at residue S935 (A–D), total LRRK2-positive cells (A’–D’) in WT PSEN1 (A,B) or PSEN1 I416T ChLNs (C,D) in the absence (A,C) or presence (B,D) of PF475. (E–G) Quantification of pS935-LRRK2-positive cells (E), total LRRK2-positive cells (F), and the pS935/total LRRK2 ratio (G). (H–K) Representative immunofluorescence merge image showing pS935-LRRK2 in WT (H,I) or PSEN1 I416T ChLNs (J,K) in the absence (H,J) or presence (I,K) of PF475 stained with antibodies against total LRRK2 (H’–K’, red fluorescence), pS935-LRRK2 (H”–K”, green fluorescence). The nuclei were counterstained using Hoechst 33342 (H’’’–K’’’, blue fluorescence). (L–N) Mean fluorescence intensity (MFI) quantification of pS935-LRRK2 (L), total LRRK2 (M), and the pS935/total LRRK2 ratio (N). Figures represent one of three independent experiments (n = 3). Results are represented as mean ± standard deviation. Statistical significance was analyzed using one-way ANOVA followed by Tukey’s test * p < 0.05, ** p < 0.01, *** p < 0.001. Images were taken at 200× magnification.

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Kinases Phosphatases - ISSN 2813-3757